| Target- | 
| Mechanism- | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePhase 2 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
 / Not yet recruitingPhase 2 A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING CLINICAL TRIAL TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF nC-001 IN PATIENTS WITH CHRONIC EUVOLEMIC HYPONATREMIA
CHRONIC EUVOLEMIC HYPONATREMIA
100 Clinical Results associated with nephcentric Inc.
0  Patents (Medical) associated with nephcentric Inc.
100 Deals associated with nephcentric Inc.
100 Translational Medicine associated with nephcentric Inc.